

B Ungar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5304739/publications.pdf>

Version: 2024-02-01

74
papers

2,459
citations

279487

23
h-index

205818

48
g-index

74
all docs

74
docs citations

74
times ranked

2435
citing authors

#	ARTICLE	IF	CITATIONS
1	Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. <i>Gut</i> , 2022, 71, 1988-1997.	6.1	6
2	P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i254-i255.	0.6	0
3	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110686.	1.4	5
4	P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i382-i382.	0.6	1
5	P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i451-i451.	0.6	0
6	Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210833.	1.4	0
7	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. <i>Vaccines</i> , 2022, 10, 376.	2.1	1
8	Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 1359.	1.0	1
9	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 91-101.	1.6	14
10	Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101503.	0.7	4
11	Dose optimisation for Loss of Response to Vedolizumabâ€™ Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1707-1719.	0.6	16
12	P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohnâ€™s disease visiting the emergency department. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S214-S214.	0.6	0
13	P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S307-S308.	0.6	0
14	Infliximab discontinuation in patients with ulcerative colitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 412-413.	3.7	0
15	Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4265.	1.0	3
16	Qualitative sonographic assessment of transmural ileal inflammation in Crohnâ€™s disease: a comparison with MRI activity score. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 961-966.	0.8	2
17	Machine learning for prediction of intra-abdominal abscesses in patients with Crohnâ€™s disease visiting the emergency department. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110531.	1.4	2
18	Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	0

#	ARTICLE	IF	CITATIONS
19	Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. United European Gastroenterology Journal, 2020, 8, 167-174.	1.6	7
20	P221 Thromboembolic events in hospitalised patients with inflammatory bowel disease – a large tertiary hospital experience. Journal of Crohn's and Colitis, 2020, 14, S253-S253.	0.6	0
21	P643 Development of quantitative ultrasonographic activity score in ileal Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S532-S533.	0.6	0
22	P160 A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S218-S219.	0.6	0
23	P402 Prediction of emergency department re-visit among Crohn's disease patients: a retrospective study. Journal of Crohn's and Colitis, 2020, 14, S372-S372.	0.6	0
24	Prediction of Recurrent Emergency Department Visits among Patients with Crohn's Disease: A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3651.	1.0	2
25	Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. Inflammatory Bowel Diseases, 2020, 26, 1619-1625.	0.9	12
26	Predictors of mortality in inflammatory bowel disease patients treated for pneumonia. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093945.	1.4	1
27	Long-term outcome of ulcerative proctitis. United European Gastroenterology Journal, 2020, 8, 847-848.	1.6	1
28	Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease – Are We There Yet?. Journal of Clinical Medicine, 2020, 9, 2753.	1.0	5
29	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterology Journal, 2020, 8, 1076-1085.	1.6	35
30	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. United European Gastroenterology Journal, 2020, 8, 418-424.	1.6	24
31	A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. United European Gastroenterology Journal, 2020, 8, 544-551.	1.6	38
32	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1330-1339.	0.9	8
33	Editorial: is vedolizumab effective for perianal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2020, 51, 912-913.	1.9	1
34	Infliximab levels and antibodies in IBD-related peripheral arthralgia. International Journal of Colorectal Disease, 2020, 35, 1141-1148.	1.0	5
35	Infliximab – Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. Gastroenterology, 2019, 157, 1338-1351.e8.	0.6	24
36	Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease, 2019, 51, 1232-1240.	0.4	59

#	ARTICLE	IF	CITATIONS
37	Letter: doubleâ€dose intensificationâ€a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 822-823.	1.9	0
38	Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohnâ€™s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1813-1821.	0.9	16
39	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. <i>Digestive and Liver Disease</i> , 2019, 51, 1106-1111.	0.4	10
40	P571 Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S399-S400.	0.6	3
41	Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNF± Antagonists. <i>Frontiers in Immunology</i> , 2019, 10, 2921.	2.2	38
42	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel diseaseâ€The Israeli real world experience. <i>Digestive and Liver Disease</i> , 2019, 51, 68-74.	0.4	24
43	Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an antiâ€tumour necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1117-1125.	1.9	13
44	Association of Vedolizumab Level, Anti-Drug Antibodies, and Î±4Î²7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 697-705.e7.	2.4	103
45	Vedolizumab in IBDâ€Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 245-257.	0.6	119
46	Early drug and antiâ€infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 212-218.	1.9	63
47	P189 Diffusion-weighted magnetic resonance enterography for prediction of response to tumour necrosis factor inhibitors in stricturing Crohnâ€™s disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S194-S194.	0.6	0
48	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1410-1417.	0.6	7
49	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ±ve Patients With Inflammatory Bowel Diseaseâ€A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56
50	Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohnâ€™s disease. <i>Abdominal Radiology</i> , 2018, 43, 3207-3212.	1.0	15
51	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naÃ±ve patients with inflammatory bowel disease: a multicentre retrospective European Crohnâ€™s and Colitis Organisation study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S029-S030.	0.6	2
52	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 890-898.	0.2	67
53	Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 507-512.	0.9	25
54	Association of Induction Infliximab Levels With Clinical Response in Perianal Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw182.	0.6	85

#	ARTICLE	IF	CITATIONS
55	Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 760-762.	1.9	4
56	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 404-408.	0.9	84
57	Rephrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2017, 5, 880-886.	1.6	15
58	Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 69-75.	2.4	24
59	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 276-282.	1.9	98
60	Advances in the development of new biologics in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2016, 29, 243-8.	0.4	41
61	PTU-072...Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016, 65, A88-A89.	6.1	0
62	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1509-1510.	2.4	1
63	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1293-1299.	1.9	72
64	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	2.4	39
65	Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 752-753.	0.6	1
66	Optimizing Anti-TNF Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 550-557.e2.	2.4	312
67	Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. <i>Gut</i> , 2016, 65, 1132-1138.	6.1	148
68	Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure. <i>Medicine (United States)</i> , 2015, 94, e673.	0.4	16
69	Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 356-364.	1.9	74
70	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 522-530.e2.	2.4	268
71	Significance of low level infliximab in the absence of anti-infliximab antibodies. <i>World Journal of Gastroenterology</i> , 2015, 21, 1907.	1.4	19
72	Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 491-498.	0.7	26

#	ARTICLE	IF	CITATIONS
73	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. <i>Gut</i> , 2014, 63, 1258-1264.	6.1	266
74	Severe and Morbid Obesity in Crohn's Disease Patients: Prevalence and Disease Associations. <i>Digestion</i> , 2013, 88, 26-32.	1.2	28